Evaluation of the efficacy of 2',3'-dideoxycytidine against adenovirus infection in a mouse pneumonia model

Antiviral Research

Volumn 47, Issue 2, 2000, Pages 79-87

  Mentel, Renate ^a   Wegner, Ursula ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

Adenovirus; Antiviral; ddC; Pneumonia model in mouse

Indexed keywords

3' FLUOROTHYMIDINE; CIDOFOVIR; TUMOR NECROSIS FACTOR ALPHA; VIRUS DNA; ZALCITABINE;

ADENOVIRUS; ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIMICROBIAL THERAPY; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HISTOPATHOLOGY; INCUBATION TIME; LUNG INJURY; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS INHIBITION; VIRUS LOAD; VIRUS PNEUMONIA; VIRUS REPLICATION;

ADENOVIRIDAE INFECTIONS; ADMINISTRATION, ORAL; ANIMAL; DNA, VIRAL; FEMALE; LUNG; MASTADENOVIRUS; MICE; MICE, INBRED BALB C; PNEUMONIA, VIRAL; POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR; ZALCITABINE;

EID: 0033825848     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(00)00088-7     Document Type: Article

References (34)

1. Allard A., Girones R., Juto P., Wadell G. Polymerase chain reaction for detection of adenoviruses in stool samples. J. Clin. Microbiol. 28:1990;2659-2667.
2. Baba M., Mori S., Shigeta S., De Clercq E. Selective inhibitory effect of (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine and 2′-nor-cyclic GMP on adenovirus replication in vitro. Antimicrob. Agents Chemother. 31:1987;337-339.
3. Berencsi K., Uri A., Valyi-Nagy T., Valyi-Nagy I., Meignier B., Peretz F.V., Rando R.F., Plotkin S.A., Gönczöl E. Early region 3-replacement adenovirus recombinants are less pathogenic in cotton rats and mice than early region 3-deleted viruses. Lab. Invest. 71:1994;350-358.
4. Childs R., Sanchez C., Engler H., Preuss J., Rosenfeld S., Dunbar C., van Rhee F., Plante M., Phang S., Barrett A.J. High incidence of adeno- and polyomavirus-induced hemorrhagic cystitis in bone marrow allotransplantation for hematological malignancy following T cell depletion and cyclosporine. Bone Marrow Transplant. 22:1998;889-893.
5. De Clercq E. Therapeutic potential of HPMPC as an antiviral drug. Rev. Med. Virol. 3:1993;85-96.
6. De Clercq E. Therapeutic potential of cidofovir (HPMPC, Vistide™) for the treatment of DNA virus (i.e. herpes-, papova-, pox- and adenovirus) infections. Verh. K. Acad. Geneeskd. Belg. 58:1996;19-49.
7. De Clercq E. New perspectives for the treatment of HIV infections. Verh. K. Acad. Geneeskd. Belg. 60:1998;13-45.
8. De Clercq E., Sakuma T., Baba M., Pauwels R., Balzarini J., Rosenberg I., Holý A. Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines. Antiviral Res. 8:1987;261-272.
9. De Oliviera C.B.R., Stevenson D., La Bree L., McDonnell P.J., Trousdale M.D. Evaluation of cidofovir (HPMPC, GS-504) against adenovirus type 5 infection in vitro and in a New Zealand rabbit ocular model. Antiviral Res. 31:1996;165-172.
10. Eggerding F.A., Pierce W.C. Molecular biology of adenovirus type 2 semi-permissive infections. I. Viral growth and expression of viral replicative functions during restricted adenovirus infection. Virology. 15:1986;97-113.
11. Ginsberg H.S., Moldawer L.L., Sehgal P.B., Redington M., Kilian P.L., Chanock R.M., Prince G.A. A mouse model for investigating the molecular pathogenesis of adenovirus pneumonia. Proc. Natl. Acad. Sci. USA. 88:1991;1651-1655.
12. Ginsberg H.S., Prince G.A. The molecular basis of adenovirus pathogenesis. Infect. Agents Dis. 3:1994;1-8.
13. Gordon Y.J., Romanowski E., Araullo-Cruz T., Seaberg L., Erzurum S., Tolman R., De Clercq E. Inhibitory effect of (S)-HPMPC, (S)-HPMPA, and 2′-nor-cyclic GMP on clinical ocular adenoviral isolates is serotype-dependent in vitro. Antiviral Res. 16:1991;11-16.
14. Gordon Y.J., Romanowski E., Araullo-Cruz T., De Clercq E. Pretreatment with topical 0.1% (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine inhibits adenovirus type 5 replication in the New Zealand rabbit ocular model. Cornea. 11:1992;529-533.
15. Gordon Y.J., Naesens L., De Clercq E., Maudgal P.C., Veckeneer M. Treatment of adenoviral conjunctivitis with topical cidofovir. Cornea. 15:1996;546.
16. Hierholzer J.C. Adenoviruses in the immunocompromised host. Clin. Microbiol. Rev. 5:1992;262-274.
17. Hirsch M.S., D′Aquila R.T. Therapy for human immunodeficiency virus infection. N. Engl. J. Med. 328:1993;1686-1695.
18. Hui M.B.V., Lien E.J., Trousdale M.D. Inhibition of human adenoviruses by 1-(2′-hydroxy-5′-methoxybenzylidene)amino-3-hydroxyguanidine tosylate. Antiviral Res. 24:1994;261-273.
19. Kassianides C., Hoofnagle J.H., Miller R.H., Doo E., Ford H., Broder S., Mitsuya H. Inhibition of duck hepatitis B virus replication by 2′,3′-dideoxycytidine. A potent inhibitor of reverse transcriptase. Gastroenterology. 97:1989;1275-1280.
20. Kelley J.A., Litterst C.L., Roth J.S., Vistica D.T., Poplack D.G., Cooney D.A., Nadkarni M., Balis F.M., Broder S., Johns D.G. The disposition and metabolism of 2′,3′-dideoxycytidine, an in vitro inhibitor of human T-lymphotrophic virus type III infectivity, in mice and monkeys. Drug Metab. Dispos. 15:1987;595-601.
21. Liebermann H., Mentel R. Quantification of adenovirus particles. J. Virol. Methods. 50:1994;281-291.
22. Liebermann H., Mentel R., Döhner L., Modrow S., Seidel W. Inhibition of cell adhesion to the virus by synthetic peptides of fiber knob of human adenovirus serotypes 2 and 3 and virus neutralization by anti-peptide antibodies. Virus Res. 45:1996;111-121.
23. Liebermann H., Mentel R., Bauer U., Pring-Akerblom P., Dölling R., Modrow S., Seidel W. Receptor binding sites and antigenic epitopes on the fiber knob of human adenovirus serotype 3. J. Virol. 72:1998;9121-9130.
24. Lucher L.A. Abortive adenovirus infection and host range determinants. Doerfler W., Böhm P. The Molecular Repertoire of Adenoviruses. 1995;Springer-Verlag, Heidelberg, Berlin, New York.
25. Mentel R., Jacker S., Wegner U. Studies on the development of an adenovirus infection model in hamsters. Hyg. Med. 18:1993;489-493.
26. Mentel R., Matthes E., von Janta-Lipinski M., Wegner U. Fluorescent focus reduction assay for the screening of antiadenoviral agents. J. Virol. Methods. 59:1996a;99-104.
27. Mentel R., Döpping G., Wegner U., Seidel W., Liebermann H., Döhner L. Adenovirus-receptor interaction with human lymphocytes. J. Med. Virol. 51:1996b;252-257.
28. Mentel R., Kinder M., Wegner U., von Janta-Lipinski M., Matthes E. Inhibitory activity of 3′-fluoro-2′deoxythymidine and related nucleoside analogues against adenovirus in vitro. Antiviral Res. 34:1997;113-119.
29. Mentel R., Kurek S., Wegner U., von Janta-Lipinski M., Matthes E., Gürtler L. Inhibition of Adenovirus DNA polymerase by modified nucleoside triphosphate analogues correlate with their antiviral effects on cellular level. Abstr. VP27.12 p. 309. 1999;In Abstract book of the XIth International Congress of Virology, Sydney, Australia.
30. Munoz F.M., Piedra P.A., Demmler G.J. Disseminated adenovirus disease in immunocompromised and immunocompetent children. Clin. Infect. Dis. 27:1998;1194-1200.
31. Sparer T.E., Tripp R.A., Dillehay D.L., Hermiston T.W., Wold W.S.M., Gooding L.R. The role of human adenovirus early region 3 proteins (gp19K, 10.4K, 14.5K, and 14.7K) in a murine pneumonia model. J. Virol. 70:1996;2431-2439.
32. Toltzis P., Mourton T., Magnuson T. Comparative embryonic cytotoxicity of antiretroviral nucleosides. J. Infect. Dis. 169:1994;1100-1102.
33. Tsai J.C., Garlinghouse G., McDonnell P.J., Trousdale M.D. An experimental animal model of adenoviruis-induced ocular disease. The cotton rat. Arch. Ophthalmol. 110:1992;1167-1170.
34. Zarraga A.L., Kerns F.T., Kitchen L.W. Adenovirus pneumonia with severe sequelae in an immunocompetent adult. Clin. Infect. Dis. 15:1992;712-713.